# Single-agent versus combination regimens containing propofol: a retrospective cohort study of recovery metrics and complication rates in a hospital-based endoscopy suite

**Authors:** Guozhen Xie, Maria Estevez, Kiyan Heybati, Matthew Vogt, Michael Smith, Christine Moshe, Johanna Chan, Vivek Kumbhari, Ryan Chadha

PMC · DOI: 10.1016/j.bjane.2025.844602 · 2025-02-27

## TL;DR

This study compares recovery times and complications when using propofol alone versus with other sedatives during endoscopy procedures.

## Contribution

The study provides new evidence on how different sedative combinations with propofol affect recovery and complication rates in endoscopy.

## Key findings

- Propofol combined with fentanyl led to longer recovery times and higher hypoxia rates.
- Dexmedetomidine with propofol reduced hypoxia and hospitalization but increased bradycardia.
- Most adjuvant sedatives did not prolong recovery times, except fentanyl.

## Abstract

Anesthesiologists are often tasked with overseeing sedation in non-surgical settings. We aim to determine whether adding adjuvant sedatives to propofol affects the recovery times and complication rates after endoscopy.

We conducted a retrospective cohort study of adults (≥18) who received propofol while undergoing esophagogastroduodenoscopy (EGD) and/or colonoscopy (COL) at a large academic institution over a four-year period. Patients receiving propofol alone were compared against patients receiving propofol in combination with midazolam, fentanyl, ketamine, or dexmedetomidine. The primary outcome was PACU length of stay, adjusted for age, sex, and ASA Score. Secondary outcomes included incidence of PACU postoperative nausea and vomiting, hypoxemia (SpO2 < 90%), bradycardia (HR < 60 bpm), and escalation of care (hospital admission), reported in adjusted odds ratios and their 95% confidence intervals.

Across the study period, 28,532 cases were included. Colonoscopies performed under propofol+fentanyl sedation were associated with significantly longer PACU LOS compared to propofol alone. Adjusted mean PACU LOS was significantly longer in patients receiving adjuvant fentanyl, compared to propofol alone (p < 0.01) and propofol + dexmedetomidine (p < 0.01). Patients receiving propofol alone exhibited a 9.4% incidence of bradycardia, 16.0% hypoxia, 0.89% PONV, and 0.40% hospitalization. Adjuvant fentanyl use was associated with higher odds of hypoxia across all procedure types (p < 0.05). Adjuvant dexmedetomidine was associated with higher rates of bradycardia, but lower rates of hypoxia, PONV, and hospitalization (p < 0.05).

With the exception of fentanyl, combining propofol with other sedatives was not associated with longer recovery times. The incidence of complications differed significantly with the use of adjuvant fentanyl or dexmedetomidine.

## Linked entities

- **Chemicals:** propofol (PubChem CID 4943), midazolam (PubChem CID 4192), fentanyl (PubChem CID 3345), ketamine (PubChem CID 3821), dexmedetomidine (PubChem CID 5311068)

## Full-text entities

- **Diseases:** complication (MESH:D008107), PONV (MESH:D020250), bradycardia (MESH:D001919), hypoxemia (MESH:D000860)
- **Chemicals:** fentanyl (MESH:D005283), dexmedetomidine (MESH:D020927), fent (-), midazolam (MESH:D008874), propofol (MESH:D015742)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11951190/full.md

---
Source: https://tomesphere.com/paper/PMC11951190